“2021 Analysis of the Chinese Clinical Chemistry and Immunodiagnostic Markets” is a new strategic analysis of the major business opportunities emerging in the Chinese clinical chemistry and immunodiagnostic markets during the next five years. The report provides specimen, test volume and sales forecasts; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years. The report presents five-year test volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays as well as controls, calibrators and consumables. Rationale The Chinese clinical chemistry and immunodiagnostics market is undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators. Tests Analyzed in the Report Routine Clinical Chemistry Albumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, AST/SGOT, Bilirubin, Total, BUN (Blood Urea Nitrogen), Calcium, Cardio CRP, Carbon Dioxide/Bicarbonate, Chloride, Cholesterol, Creatine Kinase (CK), CK-MB, Creatinine, CRP, Ferritin, GGT, Glucose, HDL Cholesterol, Homocysteine, Iron, LDH, LDL Cholesterol, Magnesium, Phosphorus, Potassium, Protein, Total, Sodium, Triglycerides, Troponin, Uric Acid. Therapeutic Drug Monitoring (TDM) Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam,
Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin. Endocrine Function Cortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH,
Prolactin, T3, T3 Uptake, Free T3, T4, Free T4, TBG, Testosterone,
Thyroglobulin Ab, TPO Ab, TSH. Tumor Markers and Special Chemistry AFP, CA 15-3/27-29, CA 19-9, CEA, Ferritin, Follate (Folic Acid),
Glycosylated Hemoglobin, HCG, 25-Hydroxy Vitamin D2 and D3, Occult Blood,
PAP, PSA, Thyroglobulin, Vitamin B-12. Immunoproteins C3, C4, Free Light Chains, Haptoglobin, IgA, IgE Specific, IgE Total, IgG, IgM,
Immunofixation, Prealbumin, Protein Electrophoresis. Drugs of Abuse Amphetamines, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine,
LSD, Methadone, Methaqualone, Opiates, Phencyclidine (PCP),
Propoxyphene, Tricyclic Antidepressants. Current and Emerging Products - Analysis of current and emerging clinical chemistry
and immunodiagnostic tests. - Review of current instrumentation technologies, and feature comparison
of high-, medium-, and low-volume/POC analyzers. Technology Assessment - Assessment of current and emerging
technologies, and their potential market applications. - Comprehensive lists of companies developing
or marketing new technologies and products, by test. Strategic Recommendations - New product development opportunities
with significant market appeal. - Alternative market penetration strategies. - Potential market entry barriers and risks. Competitive Assessments - Strategic assessments of major suppliers and
emerging market entrants, including their sales, product
portfolios, marketing tactics, collaborative
arrangements and new products in R&D. - The companies analyzed in the report include
Abbott, AdnaGen, Agilent, Alere, Beckman Coulter/Danaher,
Biomedical Diagnostics, bioMerieux, Bio-Rad, DiaSorin,
Eiken, Fujirebio/Innogenetics, IL, Kyowa Medex,
Ortho-Clinical Diagnotics, Roche, Siemens, Sysmex,
Thermo Fisher, Tosoh, Wako, Wallac/PE. Contains 517 pages and 65 tables
|